Brief: Medivir: MIV-818 Well-Tolerated By Patients, According To Phase Ia Study

Medivir AB

13/06/2019 08:14

June 13 (Reuters) - Medivir AB  MVIRb.ST :
    * SELECTIVE EFFECT SIGNAL ON LIVER CANCER TISSUE IN PHASE IA
STUDY
WITH MIV-818
    * EVALUATED DOSES HAVE BEEN SHOWN TO BE WELL-TOLERATED BY
PATIENTS
    * AN EFFECT SIGNAL, MEASURED AS DNA DAMAGE, HAS BEEN
OBSERVED IN
LIVER BIOPSIES FROM TUMOR TISSUE IN MIV-818 TREATED PATIENTS
    * IN CONTRAST TO TUMOR, NORMAL LIVER TISSUE DOES NOT APPEAR
TO
HAVE BEEN AFFECTED BY TREATMENT.
    * THIS TUMOR SELECTIVE EFFECT WAS OBSERVED AT LOW MEASURED
LEVELS
OF MIV-818 IN PLASMA AND IS AN EARLY INDICATION THAT MIV-818
WORKS AS EXPECTED,

Source text for Eikon:  ID:nWkr9SQqCL 
Further company coverage:  MVIRb.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))